Unilife Signs Commercial Supply Agreement with MedImmune
Nov 04, 2015, 09:00 ET
YORK, Pa., Nov. 4, 2015 /PRNewswire/ -- Unilife Corporation (NASDAQ:UNIS, ASX: UNS), a U.S. based designer, developer and supplier of injectable drug delivery systems, today announced the signing of the first supply agreement under its November 2013 Master Development and Supply Agreement ("MDSA") with MedImmune, the global biologics research and development arm of AstraZeneca.
This supply agreement, executed on October 30, 2015, provides commercial terms for the long-term supply of a customized device from Unilife's Precision-Therapy™ platform of wearable injectors for a monoclonal antibody in late-stage clinical studies in MedImmune's pipeline.
The supply agreement follows the master terms defined in the MDSA for the customization and supply of Unilife's wearable injectors for use with MedImmune's drug candidates. The customization phase of the lead wearable injector program for Medimmune is now nearing completion and device production has begun at Unilife. Additionally, Unilife is shipping wearable injectors to MedImmune this quarter. In addition to development and material fees already paid by MedImmune, Unilife will begin generating revenue from the sale of these devices in the current quarter of this fiscal year.
Unilife has now completed its device component design verification and successful independent human factors studies for this device, as well as the qualification of filling of this wearable injector drug container for future filling on high-speed biopharmaceutical filling lines.
This new Supply Agreement provides minimum purchase commitments from MedImmune for the initial four years following the commercial launch of this biologic, and also has unit pricing for the devices.
Ian Hanson, Senior Vice-President and General Manager of Advanced Drug Delivery Systems at Unilife, said: "Unilife is pleased to be serving the needs of MedImmune, which has selected a customized device from our wearable injector platform for commercial use. We believe that our prefilled, pre-assembled and simple-to-use wearable injectors represent an attractive technology to minimize risk and maximize convenience for patients."
About Unilife Corporation
Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, insulin delivery systems, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, PA. For more information, visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.
General: UNIS-G
Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.
| Investor / PR Contacts (US): |
Analyst Enquiries |
Investor Contacts (Australia) |
| Todd Fromer / Garth Russell |
Lynn Piper |
Jeff Carter |
| KCSA Strategic Communications |
Westwicke Partners |
Unilife Corporation |
| P: + 1 212-682-6300 |
P: + 1 415-309-5999 |
P: + 61 2 8346 6500 |
SOURCE Unilife Corporation